[ScinoPharm] Announcement regarding the approval of the removal of non-compete restrictions for directors (including independent directors) and their representatives at the 116th Annual General Meeting

Key facts

  • [ScinoPharm] Announcement regarding the approval of the removal of non-compete restrictions for directors (including independent directors) and their representatives at the 116th Annual General Meeting
  • ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.
  • Source: PR Times
  • Date: May 27, 2026

Direct answer

ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.

Citation
[ScinoPharm] Announcement regarding the approval of the removal of non-compete restrictions for directors (including independent directors) and their representatives at the 116th Annual General Meeting (May 27, 2026), PR Times
Source
PR Times
Date
May 27, 2026
ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.
businessNQ 45/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 27, 2026 at 09:00
  • 🔍 Collected: May 28, 2026 at 08:00 (23h 0m after Published)
  • 🤖 AI Analyzed: May 31, 2026 at 18:52 (82h 52m after Collected)
1. Date of Shareholders' Meeting: 2026/05/27
2. Names and titles of directors permitted to engage in competitive activities: [List of directors including Luo Chih-hsien, Kao Hsiu-ling, etc.]
3. Items of competitive activities: Business items identical to the company's scope of operations.
4. Period of permission: During the term of office as a director of the company.
5. Resolution details: In accordance with Article 209 of the Company Act, the removal of non-compete restrictions was approved without prejudice to the company's interests.
6. Directors involved in mainland China businesses: Chairman Luo Chih-hsien, Director Shih Chiu-ju, Independent Director Li Ming-hsien.
7. Positions held in mainland China: Chairman Luo holds various chairmanships and directorships in Uni-President related entities. Director Shih is a director at Kunshan Xingneng Energy. Independent Director Li is an independent director at Jin Yuan Uni-President Securities (Xiamen).
8. Locations and business scopes: Detailed list of addresses and business activities including food, beverages, lithium batteries, and securities.
10. Impact on financial and business operations: None.
11. Investment amount and shareholding ratio: None.

FAQ

What is a non-compete clause for directors?

It is a legal restriction preventing directors from engaging in businesses that compete with the company they serve.

What are the key facts in this article?

ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.

What is the direct answer?

ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.